A comparison between early presentation of dementia with Lewy Bodies, Alzheimer's disease and Parkinson's disease: evidence from routine primary care and UK Biobank data.

OBJECTIVE To simultaneously contrast prediagnostic clinical characteristics of individuals with a final diagnosis of dementia with Lewy Bodies, Parkinson's disease, Alzheimer's disease compared to controls without neurodegenerative disorders. METHODS Using the longitudinal THIN database in the UK, we tested the association of each neurodegenerative disorder with a selected list of symptoms and broad families of treatments, and compared the associations between disorders to detect disease-specific effects. We replicated the main findings in the UK Biobank. RESULTS We used data of 28,222 patients with PD, 20,214 with AD, 4,682 with DLB and 20,214 controls. All neurodegenerative disorders were significantly associated with the presence of multiple clinical characteristics before their diagnosis including sleep disorders, falls, psychiatric symptoms and autonomic dysfunctions. When comparing DLB patients with patients with PD and AD patients, falls, psychiatric symptoms and autonomic dysfunction were all more strongly associated with DLB in the five years preceding the first neurodegenerative diagnosis. The use of statins was lower in patients who developed PD and higher in patients who developed DLB compared to AD. In PD patients, the use of statins was associated with the development of dementia in the five years following PD diagnosis. INTERPRETATION Prediagnostic presentations of falls, psychiatric symptoms and autonomic dysfunctions were more strongly associated with DLB than PD and AD. This study also suggests that whilst several associations with medications are similar in neurodegenerative disorders, statin usage is negatively associated with Parkinson's Disease but positively with DLB and AD as well as development of dementia in PD. This article is protected by copyright. All rights reserved.

[1]  S. Durrleman,et al.  Identifying health conditions associated with Alzheimer's disease up to 15 years before diagnosis: an agnostic study of French and British health records. , 2022, The Lancet. Digital health.

[2]  Lin F. Yang,et al.  Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019 , 2022, The Lancet. Public health.

[3]  S. Durrleman,et al.  Data-driven identification of health conditions associated with incident Alzheimer's disease dementia risk: a 15 years follow-up cohort from electronic health records in France and the United Kingdom , 2021, medRxiv.

[4]  S. Fereshtehnejad,et al.  Prodromal Parkinson disease subtypes — key to understanding heterogeneity , 2021, Nature Reviews Neurology.

[5]  T. Foltynie,et al.  Diabetes medications and risk of Parkinson’s disease: a cohort study of patients with diabetes , 2020, Brain : a journal of neurology.

[6]  D. Brooks,et al.  Brain-first versus body-first Parkinson's disease: a multimodal imaging case-control study. , 2020, Brain : a journal of neurology.

[7]  Naaheed Mukadam,et al.  Dementia prevention, intervention, and care: 2020 report of the Lancet Commission , 2020, The Lancet.

[8]  C. Carroll,et al.  Simvastatin as a neuroprotective treatment for Parkinson’s disease (PD STAT): protocol for a double-blind, randomised, placebo-controlled futility study , 2019, BMJ Open.

[9]  K. Wirdefeldt,et al.  Lipids, Apolipoproteins, and The Risk of Parkinson's Disease: A Prospective Cohort Study and a Mendelian Randomization Analysis. , 2019, Circulation research.

[10]  A. Sinclair,et al.  Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and APOE genotype , 2019, Alzheimer's & Dementia.

[11]  Daniela Berg,et al.  Prodromal Parkinson's Disease: The Decade Past, the Decade to Come , 2019, Movement disorders : official journal of the Movement Disorder Society.

[12]  P. Visscher,et al.  Genome-wide association study of medication-use and associated disease in the UK Biobank , 2019, Nature Communications.

[13]  M. Stamelou,et al.  Mediterranean diet adherence is related to reduced probability of prodromal Parkinson's disease , 2018, Movement disorders : official journal of the Movement Disorder Society.

[14]  Yoshihiro Kokubo,et al.  Global, regional, and national burden of Parkinson's disease, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016 , 2018, The Lancet Neurology.

[15]  P. Donnelly,et al.  The UK Biobank resource with deep phenotyping and genomic data , 2018, Nature.

[16]  L. Petrucelli,et al.  Converging pathways in neurodegeneration, from genetics to mechanisms , 2018, Nature Neuroscience.

[17]  Nir Giladi,et al.  Higher serum cholesterol and decreased Parkinson's disease risk: A statin‐free cohort study , 2018, Movement disorders : official journal of the Movement Disorder Society.

[18]  D. Berlau,et al.  The role of statins in both cognitive impairment and protection against dementia: a tale of two mechanisms , 2018, Translational Neurodegeneration.

[19]  Yue Huang,et al.  Reader response: Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium , 2018, Neurology.

[20]  David S. Park,et al.  β2-Adrenoreceptor is a regulator of the α-synuclein gene driving risk of Parkinson’s disease , 2017, Science.

[21]  Tudor I. Oprea,et al.  A comprehensive map of molecular drug targets , 2016, Nature Reviews Drug Discovery.

[22]  B. Boeve,et al.  Lewy body dementias , 2015, The Lancet.

[23]  F. Sacks,et al.  MIND diet associated with reduced incidence of Alzheimer's disease , 2015, Alzheimer's & Dementia.

[24]  Xuemei Huang,et al.  Statins, plasma cholesterol, and risk of Parkinson's disease: A prospective study , 2015, Movement disorders : official journal of the Movement Disorder Society.

[25]  T. Kawada Predictors of dementia in Parkinson disease: A prospective cohort study , 2015, Neurology.

[26]  R. Postuma,et al.  Parkinson risk in idiopathic REM sleep behavior disorder , 2015, Neurology.

[27]  S. Villapol,et al.  Neuroprotective effects of angiotensin receptor blockers. , 2015, American journal of hypertension.

[28]  K. Walters,et al.  Prediagnostic presentations of Parkinson's disease in primary care: a case-control study , 2015, The Lancet Neurology.

[29]  R. Postuma,et al.  Prodromal autonomic symptoms and signs in Parkinson's disease and dementia with Lewy bodies , 2013, Movement disorders : official journal of the Movement Disorder Society.

[30]  P. Hedera,et al.  Pharmacotherapy of Essential Tremor , 2013, Journal of central nervous system disease.

[31]  J. Dartigues,et al.  Benzodiazepine use and risk of dementia: prospective population based study , 2012, BMJ : British Medical Journal.

[32]  A. Bourke,et al.  Generalisability of The Health Improvement Network (THIN) database: demographics, chronic disease prevalence and mortality rates. , 2011, Informatics in primary care.

[33]  P. Rose,et al.  Validity of diagnostic coding within the General Practice Research Database: a systematic review. , 2010, The British journal of general practice : the journal of the Royal College of General Practitioners.

[34]  L. Werdelin,et al.  Constipation in neurological diseases , 2003, Journal of neurology, neurosurgery, and psychiatry.